blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1692101

EP1692101 - MERCAPTO-PHENYL-NAPHTHYL-METHANE DERIVATIVES AND PREPARATION THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.05.2012
Database last updated on 24.08.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Council of Scientific and Industrial Research
Rafi Marg
New Delhi 110 001 / IN
[2011/27]
Former [2006/34]For all designated states
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Rafi Marg
New Delhi 110 001 / IN
Inventor(s)01 / SANGITA
Central Drug Research Inst., Chattar Manzil Palace
Lucknow, 226 001 Uttar Pradesh / IN
02 / KUMAR, Atul
Central Drug Research Inst., Chattar Manzil Palace
Lucknow, 226 001 Uttar Pradesh / IN
03 / SINGH, Man Mohan
Central Drug Research Inst., Chattar Manzil Palace
Lucknow, 226 001 Uttar Pradesh / IN
04 / JAIN, Girish Kumar
Central Drug Research Inst., Chattar Manzil Palace
Lucknow, 226 001 Uttar Pradesh / IN
05 / MURTHY, Puvvada Sri Ramchandra
Central Drug Research Inst., Chattar Manzil Palace
Lucknow, 226 001 Uttar Pradesh / IN
06 / RAY, Suprabhat
Central Drug Research Inst., Chattar Manzil Palace
Lucknow, 226 001 Uttar Pradesh / IN
 [2006/34]
Representative(s)Schwarz, Albin, et al
Schwarz & Partner Patentanwälte Wipplingerstrasse 30
1010 Wien / AT
[N/P]
Former [2006/34]Schwarz, Albin, et al
Kopecky & Schwarz Patentanwälte Wipplingerstrasse 32/22
1010 Wien / AT
Application number, filing date03780487.923.12.2003
[2006/34]
WO2003IB06247
Priority number, dateUS20030458401P31.03.2003         Original published format: US 458401 P
[2006/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004087644
Date:14.10.2004
Language:EN
[2004/42]
Type: A1 Application with search report 
No.:EP1692101
Date:23.08.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 14.10.2004 takes the place of the publication of the European patent application.
[2006/34]
Type: B1 Patent specification 
No.:EP1692101
Date:06.07.2011
Language:EN
[2011/27]
Search report(s)International search report - published on:EP14.10.2004
ClassificationIPC:C07C317/22, C07C317/24, C07C323/19, C07C323/22, C07C323/25, C07D295/088, A61K31/10, A61K31/12, A61K31/145, A61K31/222, A61K31/40, A61K31/4453, A61P5/30
[2006/34]
CPC:
C07D295/088 (EP,US); A61P19/08 (EP); A61P25/28 (EP);
A61P35/00 (EP); A61P5/30 (EP); C07C317/22 (EP,US);
C07C317/24 (EP,US); C07C323/19 (EP,US); C07C323/22 (EP,US);
C07C323/25 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2006/34]
TitleGerman:MERCAPTOPHENYLNAPHTHYLMETHAN-DERIVATE UND DEREN HERSTELLUNG[2006/34]
English:MERCAPTO-PHENYL-NAPHTHYL-METHANE DERIVATIVES AND PREPARATION THEREOF[2006/34]
French:DERIVES DE MERCAPTO-PHENYLE-NAPHTHYLE-METHANE ET LEUR PREPARATION[2006/34]
Entry into regional phase31.10.2005National basic fee paid 
31.10.2005Designation fee(s) paid 
31.10.2005Examination fee paid 
Examination procedure22.07.2005Request for preliminary examination filed
International Preliminary Examining Authority: EP
31.10.2005Examination requested  [2006/34]
23.03.2007Despatch of a communication from the examining division (Time limit: M06)
02.10.2007Reply to a communication from the examining division
26.10.2007Despatch of a communication from the examining division (Time limit: M06)
30.04.2008Reply to a communication from the examining division
15.09.2008Date of oral proceedings
10.10.2008Minutes of oral proceedings despatched
20.10.2008Communication of intention to grant the patent
17.02.2009Fee for grant paid
17.02.2009Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.03.2007
Opposition(s)11.04.2012No opposition filed within time limit [2012/24]
Fees paidRenewal fee
28.12.2005Renewal fee patent year 03
27.12.2006Renewal fee patent year 04
28.12.2007Renewal fee patent year 05
30.12.2008Renewal fee patent year 06
30.12.2009Renewal fee patent year 07
27.12.2010Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
HU06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
TR06.07.2011
BG06.10.2011
GR07.10.2011
ES17.10.2011
PT07.11.2011
IE23.12.2011
LU23.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
[2013/45]
Former [2013/44]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
TR06.07.2011
BG06.10.2011
GR07.10.2011
ES17.10.2011
PT07.11.2011
IE23.12.2011
LU23.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
Former [2013/29]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
BG06.10.2011
GR07.10.2011
ES17.10.2011
PT07.11.2011
IE23.12.2011
LU23.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
Former [2013/25]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
ES17.10.2011
PT07.11.2011
IE23.12.2011
LU23.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
Former [2013/22]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
ES17.10.2011
PT07.11.2011
IE23.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
Former [2012/49]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
PT07.11.2011
IE23.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
Former [2012/47]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
PT07.11.2011
IE23.12.2011
MC31.12.2011
Former [2012/33]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
PT07.11.2011
MC31.12.2011
Former [2012/31]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
DK06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
PT07.11.2011
Former [2012/23]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
EE06.07.2011
FI06.07.2011
IT06.07.2011
NL06.07.2011
RO06.07.2011
SE06.07.2011
SI06.07.2011
SK06.07.2011
GR07.10.2011
PT07.11.2011
Former [2012/21]AT06.07.2011
BE06.07.2011
CY06.07.2011
CZ06.07.2011
FI06.07.2011
NL06.07.2011
SE06.07.2011
SI06.07.2011
GR07.10.2011
PT07.11.2011
Former [2012/12]AT06.07.2011
BE06.07.2011
CY06.07.2011
FI06.07.2011
NL06.07.2011
SE06.07.2011
SI06.07.2011
GR07.10.2011
PT07.11.2011
Former [2012/11]AT06.07.2011
BE06.07.2011
FI06.07.2011
NL06.07.2011
SE06.07.2011
SI06.07.2011
GR07.10.2011
PT07.11.2011
Former [2012/10]BE06.07.2011
FI06.07.2011
NL06.07.2011
SE06.07.2011
SI06.07.2011
GR07.10.2011
PT07.11.2011
Former [2012/09]BE06.07.2011
FI06.07.2011
NL06.07.2011
SI06.07.2011
PT07.11.2011
Former [2012/08]NL06.07.2011
SI06.07.2011
Former [2011/52]SI06.07.2011
Cited inInternational search[X]EP0488602  (ICI PLC [GB], et al) [X] 1,3,5-21,55,58-79 * example 2, compound 6f *;
 JPH05170754  [ ] (NIPPON SODA CO);
 [X]WO9737984  (UNION PHARMA SCIENT APPL [FR], et al) [X] 1,3-21 * examples 165,166 *;
 [A]US6410564  (BRYANT HENRY U [US], et al) [A] 1-105* whole document *;
 [X]WO02100903  (CIBA SC HOLDING AG [CH], et al) [X] 1,3,5-21 * example 14 *;
 [X]  - YANG, GUOQIANG ET AL, "Triplet state and photolysis of S-phenyl 1-thionaphthoate", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY, A: CHEMISTRY, (1996), vol. 99, no. 1, pages 45 - 50, XP001181402 [X] 1,2,5-21 * Scheme 2: 4-thiobenzoyl 1-naphthalene *

DOI:   http://dx.doi.org/10.1016/1010-6030(96)04354-7
 [X]  - YOSHINAKA, SHINJI ET AL, "Preparation of monoglycidyloxy compound", CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1994:42022, URL: STN, XP002280767 [X] 1,2,5-21 * abstract *
by applicant   - "Recent developments in the chemotherapy of osteoporosis", DWIVEDI I; RAY S, Progress in Drug Research, (1995), vol. 45, pages 289 - 338
    - MARSHALL DH; HORSMANN A; NORDIN BEC, "The prevention and management of post- menopausal osteoporosis", ACTA OBSTET GYNECOL SCAND, (1977), vol. 65, pages 49 - 56
    - HUTCHINSON TA; POLANSKY SM; FEINSTEIN AR, "Postmenopausal estrogen protect against fractures of hip and distal radius: A care-control study", LANCET, (1979), vol. 2, pages 705 - 709
    - LOBO RA, "Cardiovascular implication of estrogen replacement therapy", OBSTETRICS & GYNAECOLOGY, (1990), vol. 75, pages 185 - 245
    - MENDELSON ME; KARAS RH, "Estrogen and the blood vessel wall", CURRENT OPINION IN CARDIOLOGY 1994, (1994), pages 619 - 626
    - STAMPFER MJ; COLDITZ GA, "Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence", PREVENTIVE MEDICINE, (1991), vol. 20, doi:doi:10.1016/0091-7435(91)90006-P, pages 47 - 63, XP023040594

DOI:   http://dx.doi.org/10.1016/0091-7435(91)90006-P
    - GRUBER CJ ET AL., "Production and actions of estrogens", THE NEW ENGLAND JOURNAL OF MEDICINE, (2002), vol. 346, pages 340 - 352
    - BELLINO FL; WISE PM, "Nonhuman primate models of menopause workshop", BIOLOGY OF REPRODUCTION, (2003), vol. 68, pages 10 - 18
    - LOBO RA, "Cardiovascular implication of estrogen replacement therapy", OBSTETRICS AND GYNAECOLOGY, (1990), vol. 75, pages 18S - 24S
    - MEDELSON ME; KARAS RD, "Estrogen and the blood vessel wall", CURRENT OPINION IN CARDIOLOGY, (1994), vol. 9, pages 619 - 626
    - KNNEL WH; HJORTLAND M; MCNAMARA PM, "Menopause and risk of cardiovascular disease: The Framingham Study", ANN INT MED, (1976), vol. 8, pages 5447 - 5552
    - STAMPFER MJ; COLDITZ G, "Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence", PREVENTIVE MEDICINE, (1991), vol. 20, doi:doi:10.1016/0091-7435(91)90006-P, pages 47 - 63, XP023040594

DOI:   http://dx.doi.org/10.1016/0091-7435(91)90006-P
    - DHANDAPANI KM; BRANN DW, "Protective effects of estrogen and Selective Estrogen Receptor Modulators in the brain", BIOLOGY OF REPRODUCTION, (2002), vol. 67, doi:doi:10.1095/biolreprod.102.003848, pages 1379 - 1385, XP008041031

DOI:   http://dx.doi.org/10.1095/biolreprod.102.003848
    - BERGKVIST L ET AL., "The risk of breast cancer after estrogen and estrogen-progestin replacement", N ENG J MED, (1989), vol. 321, pages 293 - 297
    - COIDITZ GA ET AL., "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women", N ENG J MED, (1995), vol. 332, page 1593
    - BAUM M ET AL., "Endometrial cancer during tamoxifen treatment", LANCET, (1994), vol. 343, page 1291
    - CLEMONS M; DANSON S; HOWELL A, "Tamoxifen ('Nolvadex'): Antitumour treatment. A review", CANCER TREATMENT REVIEWS, (2002), vol. 28, pages 165 - 180
    - HUGGINS, C; YANG NC, "Induction and extinction of mammary cancer", SCIENCE, (1962), vol. 137, pages 257 - 262
    - WILLIAMS GM ET AL., "The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat", CARCINOGENESIS, (1993), vol. 10, pages 315 - 317
    - MEIER CR; JICK H, "Tamoxifen and risk of idiopathic venous thromboembolism", BR J CLIN PHARMACOL, (1998), vol. 45, pages 608 - 612
    - SINGH MM, "Centchroman, a selective estrogen receptor modulator, as contraceptive and in the management of hormone related clinical disorders", MEDICINAL RESEARCH REVIEWS, (2001), vol. 21, pages 302 - 347
    - "Clinical evaluation of centchroman: A new oral contraceptive", NITYANAND S ET AL., Hormone Antagonists for Fertility Regulation, INDIAN SOCIETY FOR THE STUDY OF REPRODUCTION AND FERTILITY, BOMBAY, (1988), pages 241 - 410
    - "Results of multicentric trial of centchroman", PURI V ET AL., Pharmacology for Health in Asia, (1988), pages 441 - 447
    - "Contraceptive efficacy and safety of centchroman with biweekly-cum-weekly schedule", NITYANAND S ET AL., Current Concepts in Fertility Regulation and Reproduction, WILEY EASTERN LTD, (1994), pages 61 - 68
    - NITYANAND S ET AL., "Centchroman: Current Status as a contraceptive", INDIAN PROGRESS IN FAMILY WELFARE, (1995), vol. 10, pages 26 - 31
    - NITYANAND S; ANAND N, "Centchroman: A nonsteroidal antifertility agent", FOGSI FOCUS, (1996), pages 8 - 10
    - ROY SN ET AL., "Induction of ovulation in human with centchroman, a preliminary report", FERTILITY AND STERILITY, (1976), vol. 41, pages 1108 - 1110
    - GOODMAN; GILMAN, The Pharmacological Basis of Therapeutics, MACMILLAN PUBLISHING COMPANY, (1985), pages 1321 - 1041
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.